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Abstract
Background: Preterm infants are at risk for hypoxic-ischemic encephalopathy. No therapy exists to treat this brain
injury and subsequent long-term sequelae. We have previously shown in a well-established pre-clinical model of
global hypoxia-ischemia (HI) that mesenchymal stem cells are a promising candidate for the treatment of hypoxic-
ischemic brain injury. In the current study, we investigated the neuroprotective capacity of multipotent adult
progenitor cells (MAPC®), which are adherent bone marrow-derived cells of an earlier developmental stage than
mesenchymal stem cells and exhibiting more potent anti-inflammatory and regenerative properties.
Methods: Instrumented preterm sheep fetuses were subjected to global hypoxia-ischemia by 25 min of umbilical
cord occlusion at a gestational age of 106 (term ~147) days. During a 7-day reperfusion period, vital parameters
(e.g., blood pressure and heart rate; baroreceptor reflex) and (amplitude-integrated) electroencephalogram were
recorded. At the end of the experiment, the preterm brain was studied by histology.
Results: Systemic administration of MAPC therapy reduced the number and duration of seizures and prevented
decrease in baroreflex sensitivity after global HI. In addition, MAPC cells prevented HI-induced microglial
proliferation in the preterm brain. These anti-inflammatory effects were associated with MAPC-induced prevention of
hypomyelination after global HI. Besides attenuation of the cerebral inflammatory response, our findings showed that
MAPC cells modulated the peripheral splenic inflammatory response, which has been implicated in the etiology of
hypoxic-ischemic injury in the preterm brain.
Conclusions: In a pre-clinical animal model MAPC cell therapy improved the functional and structural outcome of the
preterm brain after global HI. Future studies should establish the mechanism and long-term therapeutic effects of
neuroprotection established by MAPC cells in the developing preterm brain exposed to HI. Our study may form the
basis for future clinical trials, which will evaluate whether MAPC therapy is capable of reducing neurological sequelae in
preterm infants with hypoxic-ischemic encephalopathy.
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Background
Hypoxia-ischemia (HI) in the developing brain is
strongly correlated with mortality and neurological mor-
bidity in preterm and full-term infants, resulting in an
enormous physical, psychological, and economic burden
[1]. Unfortunately, no therapeutic cure is available for
hypoxic-ischemic brain injury in preterm infants.
In a translational animal model of global HI in the
preterm ovine fetus, our group has demonstrated that
cell-based therapy may be a promising neuroprotective
strategy for preterm neonates suffering from HI-induced
brain injury [2]. We showed that intravenous adminis-
tration of exogenous mesenchymal stem cells (MSC)
protected against functional loss and structural injury of
the preterm brain [2]. These neuroprotective effects
were largely attributable to attenuation of (neuro) in-
flammatory processes, as indicated by decreased micro-
glial activation and proliferation in the preterm brain
and induction of peripheral T cell tolerance, which was
associated with reduced cerebral infiltration of these
immune effector cells [2].
Multipotent adult progenitor cells (MAPC), which are
adherent bone marrow-derived cells of an earlier
developmental stage than MSC have a high expansion
potential, and their immunological properties make it
possible to use them as a universal allogeneic donor
[3–5]. Pre-clinical animal studies have demonstrated
that in comparison to MSC, MAPC cells have stronger
anti-inflammatory effects and are more potent in promot-
ing endogenous tissue regeneration after ischemic and
traumatic injury to the CNS [6–11]. In addition, the
smaller size of MAPC cells compared to MSC facilitates
passage through the pulmonary capillary bed, which may
increase availability of MAPC cells in the systemic and
cerebral vasculature and thus enhancing their neuropro-
tective effect [12].
Based on these superior qualities of MAPC, we aimed
to assess the anti-inflammatory and neuroprotective po-
tential of MAPC cells in the preterm brain exposed to
global HI. We hypothesized that systemic administration
of MAPC cells would attenuate cerebral and peripheral
inflammation and prevent structural and functional
brain injury after global HI in the preterm ovine fetus.
We tested our hypothesis in a well-established pre-
clinical animal model of preterm global HI. In this
model, preterm ovine fetuses were exposed to global HI
by transient umbilical cord occlusion (UCO) at 0.7 ges-
tation which is equivalent to 30–32 weeks human gesta-
tion [13] followed by systemic administration of MAPC
therapy during a 7-day reperfusion period.
The anti-inflammatory effects of MAPC cells were
assessed in the preterm brain by analysis of microglial
responses in the hippocampus and subcortical white
matter. The spleen was assessed, since previous reports
suggest that MAPC-induced alterations in the splenic in-
flammatory response may be responsible for their neuro-
protective effect after brain injury [9]. Structural effects
of systemic MAPC administration were assessed by
histological white matter injury examination. Brain func-
tion was studied by analysis of cortical function by
means of electrographic seizure activity and central
(brain stem) function by means of baroreflex sensitivity.
Methods
Study approval
The experimental protocol and study design were in line
with the institutional guides for animal experiments
and were approved by the institutional Animal Ethics
Research committee of Maastricht University, The
Netherlands.
Randomization and blinding
Thirty-two singleton fetuses of time-mated Texel ewes
were randomized by an independent researcher who was
not involved in the animal experiments. Randomization
resulted in four experimental groups: (1) sham umbil-
ical cord occlusion, saline treatment (sham-SAL n = 8),
(2) sham umbilical cord occlusion, MAPC treatment
(sham-MAPC; n = 8), (3) umbilical cord occlusion, sa-
line treatment (HI-SAL; n = 8), and (4) umbilical cord
occlusion, MAPC treatment (HI-MAPC; n = 8) (Fig. 1).
The investigator performing the (sham) umbilical
cord occlusions was blinded to treatment allocation.
Tissue sampling and the analyses of brain tissue and
electrophysiological data were conducted in a blinded
fashion.
Animals and surgery
Singleton fetuses were surgically instrumented at
102 days gestational age (term ~147 days) as described
Fig. 1 Study design. Fetuses were instrumented at a gestational
age (GA) of 102 days. After a recovery period of 4 days, fetuses
were subjected to 25 min of umbilical cord occlusion (UCO) or
sham. One hour and 4 days after UCO or sham, fetuses received
either intravenous MAPC (10 million cells, closed arrow) or saline
0.9 % (open arrow). After a 7-day reperfusion period, brain tissue was
collected. Abbreviations: in instrumentation, HI hypoxia-ischemia,
SAL saline, MAPC multipotent adult progenitor cells
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previously [14]. Briefly, fetuses were partially exposed
through a midline incision. A polyurethane umbilical
vessel catheter (1.2 mm, Covidien, Mansfield, MA, USA)
was placed in the left femoral artery and brachial vein
for blood pressure recordings, blood sampling, and ad-
ministration of MAPCs. An additional catheter was
placed into the amniotic sac for measurement of amni-
otic fluid pressure. Three electrocardiogram (ECG) elec-
trodes were placed on the fetal thorax for cardiac
monitoring. Two pairs of custom-made shielded silver-
tipped electroencephalogram (EEG) electrodes (Cooner
wire Co., Chatsworth, CA, USA) were placed bilaterally
on the dura over the parasagittal parietal cortex (with a
subcutaneous silver reference electrode placed in the
neck). An inflatable vascular occluder (OC16HD,
16 mm, In Vivo Metric, Healdsburg, CA, USA) was
placed around the umbilical cord for induction of transi-
ent global HI. All fetal leads were exteriorized through
the maternal flank. Post-operatively, sheep were housed
individually with access to water and food ad libitum. A
period of 4-day post-operative recovery was incorpo-
rated before onset of the experiments.
Experimental design
At 106 days gestational age (experimental day 0) fetuses
were subjected to 25 min of (sham) umbilical cord oc-
clusion by rapidly inflating the occluder with sterile sa-
line of a defined volume known to completely inflate the
occluder. An acute drop in heart rate and a gradual de-
cline in blood pressure confirmed complete occlusion of
the umbilical cord (Fig. 2). Global hypoxia-ischemia was
further monitored with subsequent arterial blood gas
analysis indicating acidemia, hypoxemia, and hypercap-
nia (data not shown). One hour after umbilical cord oc-
clusion and on experimental day 4, fetuses received
either an intravenous bolus of MAPC cells or an equal
volume of vehicle. At the end of the experiment (ex-
perimental day 7), both ewe and fetus were euthanized
by administration of pentobarbital (200 mg/kg).
Data acquisition and analysis
Physiological data was sampled as described previously on
a custom-made MPAQ unit (Maastricht-Programmable
AcQuisition system, Maastricht Instruments BV,
Maastricht, The Netherlands) with IDEEQ software
(Maastricht Instruments BV) [14]. In short, EEG data
were sampled at 1000 Hz and stored on a hard disk
for off-line analysis. EEG data were filtered using a
0.5–30 Hz fourth order Butterworth band-pass filter.
EEG signal with an amplitude >1000 μV was consid-
ered an artifact and removed from analysis (<1 % of
data). After filtering, the raw EEG signals of the central
and posterior channels were converted into amplitude-
integrated EEG (aEEG) traces, using an (Matlab® based)
algorithm similar to the clinical EEG NicoletOne™ device
(Viasys Healthcare, Conshohocken, PA, USA), as previ-
ously described [2, 15–18]. EEG seizure activity was anno-
tated manually using aEEG/EEG traces, and the total
number and length of seizures was subsequently calcu-
lated. A neonatologist experienced in aEEG interpret-
ation, who was blinded to treatment allocation,
performed annotation.
ECG and blood pressure data were processed off-line
using MATLAB R2013a (The MathWorks, Inc., Natick,
MA). The ECG recordings were used to determine R-R
intervals. Blood pressure measurements were corrected
for amniotic pressure and used to determine the mean
arterial blood pressure in each pressure wave. As previ-
ously reported, heart rate and heart rate variability were
assessed in 192 s segment by calculating the mean R-R
interval and standard deviation (SD-RR), respectively
[19, 20]. Likewise, mean systolic blood pressure and
blood pressure variability was assessed by calculating the
mean SBP and standard deviation (SD-SBP) [19]. As a
time series estimate of baroreflex sensitivity, we calcu-
lated the ratio between SD-RR and SD-SBP [19, 21, 22].
MAPC
MAPC cells were provided by Athersys, Inc. (Cleveland
OH, USA) and stored in liquid nitrogen. Cells were pre-
pared and genomic and epigenetic stability of the cells
were confirmed as previously described [5, 23]. Flow cy-
tometric analysis of cell-surface proteins demonstrated
that the cells were CD29- and CD90-positive, and
MHC class I low, and were negative for MHC class
II, CD45, CD106, and the costimulatory molecules
CD80 and CD86. Cells were able to differentiate into
mesenchymal cell types (adipocytes, osteoblasts, chondro-
cytes, and smooth muscle cells), but also toward endothe-
lium [4]. Prior to injection, MAPC cells were thawed and
washed twice and suspended in phosphate buffered sa-
line (PBS) at a concentration of 10 × 106 cells/mL.
MAPC cells were administered intravenously 1 h and
4 days after (sham) UCO. Fetuses received two doses
of 10 × 106 cells in 1 mL PBS.
Immunohistochemistry brain
After 3 months of submersion fixation in 4 % para-
formaldehyde, the right cerebral hemisphere was em-
bedded in gelatin, and serial coronal sections (50 μm)
were cut on a Leica VT 1200S vibrating microtome
(Leica Biosystems, Nussloch, Germany). Free-floating
sections at the level of mid-thalamus and posterior
hippocampus were stained with a rabbit anti-ionized
calcium-binding adaptor molecule 1 (IBA-1) antibody
(Wako Pure Chemical Industries, Osaka, Japan) for
microglia or a rat anti-myelin basic protein (MBP)
antibody (Merck Millipore, Billerica, MA, USA) for
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myelin sheaths and myelin-producing (mature) oligo-
dendrocytes, and cleaved Caspase-3 for apoptosis
(Cell Signaling Technology, Boston, USA) as previ-
ously described [14, 24].
Briefly, endogenous peroxidase-activity was blocked by
incubation with 0.3 % H2O2 in tris-buffered saline (TBS,
pH 7.6). Free-floating sections were incubated overnight
at 4 °C with the diluted primary antibody (1:1000 anti-
IBA-1, 1:2000 MBP, 1:800 Caspase-3) followed by incu-
bation with the appropriate secondary antibodies. The
immunostaining was enhanced with Vectastain ABC
peroxidase Elite kit (PK-6200, Vector Laboratories,
Burlingame, CA, USA) followed by a nickel sulfate-
diaminobenzidine (IBA-1) or 3,3′-diamniobenzidine
staining (MBP, Caspase-3). Sections were mounted on
gelatin-coated glass slides, air-dried, dehydrated in as-
cending ethanol concentrations, and cover-slipped with
PerTex.
Analysis of immunohistochemistry
Immunohistochemical stainings were analyzed as previ-
ously described [14, 24]. For the analysis of IBA-1 and MBP
Fig. 2 Reproducibility of 25 min umbilical cord occlusion (UCO) as evidenced by comparable vital parameters and blood gasses in animals
exposed to global HI. Fetal heart rate (FHR) (a) and fetal mean arterial blood pressure (MABP) (b) measurements indicated that all animals
exposed to global HI experienced the same degree of bradycardia and hypotension, respectively; means (thick line) ± SD (shaded areas) of n = 8
animals per experimental group are shown. HI hypoxia-ischemia, SAL saline, MAPC multipotent adult progenitor cells, min minutes
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immunoreactivity, digital images of the subcortical white
matter (SCWM) (×100 magnification) and hippocampus
(×20 magnification; only IBA-1) were acquired using an
Olympus AX-70 microscope (Olympus, Tokyo, Japan)
equipped with a black and white digital camera. In the
hippocampus, area fraction of IBA-1 immunoreactivity was
assessed in one digital image per section by delineat-
ing the hippocampus and determining the areal
fraction of IBA-1 immunoreactivity expressed as a
percentage of total hippocampal area with a standard
threshold using Leica Qwin Pro V 3.5.1 software
(Leica, Rijswijk, The Netherlands). In the SCWM, the
area fractions of IBA-1 and MBP immunoreactivity
were determined in five adjacent ×100 digital images
obtained in standardized locations within the SCWM
of each section. The results of five images per section
were averaged to obtain the areal fractions of IBA-1
and MBP immunoreactivity within the SCWM for
each section.
For analysis of cleaved Caspase-3, five adjacent digital
images (×100 magnification) of the SCWM were ob-
tained in standardized locations for each section. Num-
bers of Caspase-3-positive cells were determined with
Leica Qwin Pro V 3.5.1 software and averaged to obtain
cell numbers for Caspase-3 per section.
RNA extraction and quantitative real-time PCR
For real-time (RT) quantitative polymerase chain reac-
tions (qPCR), total RNA was extracted from spleen using
the SV Total RNA isolation system (Z3100; Promega,
Madison, WI, USA) according to the manufacturer’s rec-
ommendations. RT-qPCR reactions were performed in
duplicate with the SensiMix SYBR No-ROX kit (QT650-
02; Bioline Reagents Ltd) in a LightCycler 480 Instru-
ment with ovine-specific primers for interleukin IL-10
(5′-CATGGGCCTGACATCAAGGA-3′ (sense), 5′-CG





3′ (antisense). RT-qPCR results were normalized to the




Detection of MAPC was performed with a PCR for hu-
man β-2 microglobulin [2]. Genomic DNA was isolated
from snap frozen brain, spleen, and lung tissues using
the Wizard Genomic Purification Kit (Promega, Leiden,
The Netherlands) according to the manufacturer’s rec-
ommendations. PCR reactions of genomic DNA were
performed for β-2 microglobulin followed by a nested
PCR for β-2 microglobulin on the amplification product
of the first PCR.
The amplified products were separated on ethidium
bromide-stained 2 % agarose gels and captured using the
Imagemaster® VDS equipped with a CCD camera (GE
Healthcare Life Sciences (Pharmacia Biotech), Uppsala,
Sweden). Serial dilutions of MAPC cells were used as
references.
Primers used for the amplification of β-2 microglobu-
lin were 5′- GTGTCTGGGTTTCATCAATC-3′ (sense),
5′- GGCAGGCATACTCATCTTTT-3′ (antisense), 5′-
TGGGTTTCATCAATCCGACAT-3′ (nested sense)
and 5′- CTCATCTTTTTCAGTGGGGGT-3′ (nested
antisense).
Statistics
Summary statistics of animal characteristics and all out-
come variables are shown as means with 95 % confi-
dence interval (CI). Groups’ comparisons of all outcome
parameters were drawn with analysis of variance
(ANOVA) or with random intercept models in case of
repeated measurements per animal (e.g., different
sections per brain). HI (sham vs. HI) and treatment
(saline vs. MAPC) were the fixed effects. For random
intercept models, animals constituted additionally the
random effect. Variables, whose distributions were posi-
tively skewed, were log-transformed previous to statis-
tical testing. To facilitate interpretation, averages on the
log scale were back transformed to the original scale
(antilog) and were presented as geometric means and
corresponding 95 % CIs.
Seizure data, measured over time, showed pronounced
right-skewness (caused by the absence of seizures in
non-hypoxic conditions) that could not be remedied by
log transformation. Hence, for these variables, pair-wise
groups’ comparisons were performed with nonparamet-
ric Mann-Whitney tests, per individual time-point. They
are presented as medians and corresponding interquar-
tile range (IQR). A false discovery rate (FDR) of 5 %
was used for multiple testing corrections. Groups’ dif-
ferences with FDR corrected P < 0.05 were considered
statistically significant. Statistical analysis was per-
formed with IBM SPSS Statistics Version 20.0 (IBM
Corp., Armonk, NY, USA).
Statistical analysis of baroreflex data was performed
using a Bayesian multi-level model [25] to estimate the
daily effects of global HI and MAPC treatment under
hypoxic and sham conditions on the baroreflex sensitiv-
ity. This model corrects for repeated measurements and
takes into account variance between and within sub-
jects [25]. Statistical time series analysis was con-
ducted using the Stan for R package (version 2.6.0) in
R (version 3.1.1).
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Results
Animal characteristics
To test the neuroprotective potential of MAPC therapy,
we randomized 32 preterm sheep fetuses in four differ-
ent experimental groups (Fig. 1). After instrumentation
and a recovery period of 4 days, animals were subjected
to 25 min of (sham) umbilical cord occlusion (UCO) to
induce global hypoxia-ischemia (HI). MAPC cells were
administered 1 h and 4 days after UCO (Fig. 1). Fetal body
weight and gestational age did not differ significantly
between the four experimental groups (Table 1). In line
with previous reports [2, 14, 15], the fetal response to
hypoxia-ischemia was comparable in all animals exposed
to UCO (Fig. 2), indicating that the injury group (HI-SAL)
and intervention group (HI-MAPC) were exposed to a
similar degree of global hypoxia-ischemia.
MAPC reduced the cerebral inflammatory response after
global HI
The cerebral inflammatory response was studied by
assessing microglial proliferation in the subcortical white
matter and hippocampus using ionized calcium-binding
adaptor molecule 1 (IBA-1), which is a highly-specific
marker for resting and activated microglia in sheep [14].
Global HI resulted in a significant (sham-SAL vs. HI-
SAL; P < 0.001) increase of IBA-1 immunoreactivity in
the SCWM and hippocampus, indicating profound
microglial proliferation in these regions (Fig. 3a–f ).
MAPC significantly (HI-SAL vs. HI-MAPC; P = 0.043)
reduced IBA-1 immunoreactivity in the SCWM
(Fig. 3a–c). MAPC did not reduce IBA-1 immunore-
activity in the hippocampus (HI-SAL vs. HI-MAPC;
P = 0.881) (Fig. 3d–f ). No differences in IBA-1 immu-
noreactivity were observed between saline or MAPC-
treated sham-operated animals in the SCWM and
hippocampus.
MAPC prevented HI-induced white matter injury
White matter injury was studied by assessing myelin
basic protein (MBP) immunoreactivity in the SCWM.
Global HI significantly (sham-SAL vs. HI-SAL; P < 0.001)
reduced MBP immunoreactivity in the SCWM, indi-
cating HI-induced hypomyelination in this region
(Fig. 4a–c). MAPC significantly increased MBP immu-
noreactivity (HI-SAL vs. HI-MAPC; P = 0.016). No
differences in MBP immunoreactivity in the SCWM
were observed between sham animals treated with sa-
line or MAPC (Fig. 4a–c). We determined brain
weight as a surrogate for neuronal injury (Table 1).
Brain weight was significantly reduced after global HI
(sham-SAL vs. HI-SAL; P = 0.046). There was no sig-
nificant difference between saline and MAPC treat-
ment in effect on brain weight (HI-SAL vs. HI-MAPC;
P = 0.429).
Apoptotic cell death was evaluated in the SCWM by
assessment of the number of cleaved Caspase-3-positive
cells (Fig. 4d). No differences in numbers of Caspase-3-
positive cells were found 7 days after global HI (sham-
SAL vs. HI-SAL; P = 0.135). The density of apoptotic
cells remained unaffected by systemic administration of
MAPC (HI-SAL vs. HI-MAPC; P = 0.881).
We did not detect MAPC in brain, spleen, or lung
tissue 7 days after global HI (i.e., 3 days after the second
dose of MAPC) using PCR for human-specific β-2 mi-
croglobulin (data not shown).
MAPC prevented splenic involution and modulated the
peripheral inflammatory response
Splenic weight was assessed, since activation of the
splenic inflammatory response was previously shown
to be characterized by mobilization of effector im-
mune cells affecting volume and weight of the spleen
[14]. Global HI induced splenic involution in saline-
treated animals (sham-SAL vs. HI-SAL; P = 0.022)
(Fig. 5a). MAPC significantly prevented splenic invo-
lution after global HI (HI-SAL vs. HI-MAPC; P = 0.032).
The splenic cytokine profile was studied since previ-
ous findings indicated that MAPC established neuro-
protection by modulating the splenic inflammatory
response (Fig. 5b–d). Splenic IL-10 mRNA levels were
significantly increased after global HI (sham-SAL vs.
HI-SAL; P = 0.031). MAPC significantly reduced IL-10
mRNA levels in the spleen after global HI (HI-SAL vs.
HI-MAPC; P = 0.042) (Fig. 5b). IFNγ mRNA levels were
significantly increased following global HI (sham-SAL vs.
HI-SAL; P = 0.022). Systemic administration of MAPC
Table 1 Animal characteristics
sham-SAL sham-MAPC HI-SAL HI-MAPC
GA at UCO (days) 105.2 (105.0;105.5) 106.0 (105.3;106.7) 105.5 (105.1;106.0) 105.2 (104.9;105.8)
BW (g) 1690 (1516;1865) 1532 (1245;1820) 1542 (1362;1721) 1559 (1340;1779)
Brain weight (g/kg BW) 17.58 (16.04;19.12) 17.39 (14.72;20.05) 15.97 (14.43;17.51)* 16.08 (14.37;17.80)
Fetuses were subjected to umbilical cord occlusion (UCO) at a comparable gestational age (GA). Fetal body weight (BW) did not differ between experimental groups.
Brain weight corrected for body weight was significantly reduced following global HI. MAPC treatment did not prevent loss of cerebral weight. Means ± 95 % CI are
shown. Groups’ comparisons were drawn with ANOVA (sham-SAL n = 8, sham-MAPC n = 8, HI-SAL n = 8, HI-MAPC n = 8)
*P ≤ 0.05
HI hypoxia-ischemia, SAL saline, MAPC multipotent adult progenitor cells
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Fig. 3 MAPC reduced cerebral inflammation in the subcortical white matter (SCWM), but not in the hippocampus. a–b Immunohistochemical
IBA-1 staining in the SCWM at ×20 (a) and ×200 (b) magnification and hippocampus of the four experimental groups (sham-SAL n = 8, sham-MAPC
n = 5, HI-SAL n = 8, HI-MAPC n = 5). Global HI induced a profound increase of IBA-1 immunoreactivity and amoeboid morphology in both
regions, which was significantly reduced by MAPC in the SCWM, but not in the hippocampus. c–d Graphical presentation of area fraction
of IBA-1 immunoreactivity in SCWM and hippocampus. Geometric means ± 95 % CI and levels of significance are depicted, which were
calculated by the random intercept model with all repeated measures (i.e., brain sections) per animal. e–f Immunohistochemical IBA-1 staining in the
hippocampus at ×20 (e) and ×200 (f) magnification of the four experimental groups. IBA-1 IR was markedly increased and accompanied by amoeboid
morphology following global HI, which remained unaffected after MAPC treatment (sham-SAL n = 8, sham-MAPC n = 5, HI-SAL n = 8, HI-MAPC n = 5).
*P≤ 0.05, §P≤ 0.01, #P≤ 0.001. IBA-1 ionized calcium-binding adaptor molecule 1, HI hypoxia-ischemia, SAL saline, MAPC multipotent adult progenitor
cells, IR immunoreactivity. a–b Scale bars: a–e represent 1 mm, b–f 100 μm
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tended to reduce IFNγ mRNA levels, but statistical
significance was not reached (HI-SAL vs. HI-MAPC;
P = 0.078) (Fig. 5c). Global HI tended to increase
splenic TNFα mRNA levels (sham-SAL vs. HI-SAL;
P = 0.078). However, MAPC treatment significantly
reduced TNFα mRNA levels (HI-SAL vs. HI-MAPC;
P < 0.001) (Fig. 5d).
MAPC reduced seizure burden after global HI
Electrographic seizure activity was assessed to deter-
mine the effect of MAPC on cortical function after
global HI (Fig. 6a–b). Global HI induced a significant
increase in total number (Fig. 6a) and duration (Fig. 6b)
of seizures after global HI (sham-SAL vs. HI-SAL, sig-
nificant in all time-points). Seizure burden peaked
within the first 48 h following global HI with a second
small rise in activity around experimental days 4 and 5
(Fig. 6a–b). MAPC reduced seizure burden throughout
the complete reperfusion period (HI-SAL vs. HI-
MAPC, significant from experimental day 2 onwards).
Cumulative number of seizures in the complete reper-
fusion study was significantly increased after global HI
(sham-SAL vs. HI-SAL; P = 0.016) and significantly re-
duced by MAPC (HI-SAL vs. HI-MAPC; P = 0.022)
(Fig. 6a). Similarly, cumulative duration (s) of seizures
was significantly increased after global HI (sham-SAL v.
HI-SAL; P = 0.015) and significantly reduced by MAPC
(HI-SAL vs. HI-MAPC; P = 0.043) (Fig. 6b). No elec-
trographic seizure activity was detected under sham
conditions.
Fig. 4 MAPC reduced white matter injury after global HI. a–b Immunohistochemical MBP staining in the SCWM of the four experimental groups
at (a) ×100 and (b) ×200 magnification. c MBP immunoreactivity in SCWM. Global HI induced marked hypomyelination in the SCWM. MAPC
significantly prevented the decrease in MBP reactivity after global HI. The area fraction of MBP was similar in sham conditions. Geometric
means ± 95 % CI and levels of significance are depicted, which were calculated by the random intercept model with all repeated measures
(i.e., brain sections) per animal (sham-SAL n = 8, sham-MAPC n = 5, HI-SAL n = 8, HI-MAPC n = 5). d Numbers of Caspase-3-positive cells in
the four experimental groups; geometric means ± 95 % CI and levels of significance are depicted, which were calculated with ANOVA
(sham-SAL n = 8, sham-MAPC n = 8, HI-SAL n = 8, HI-MAPC n = 8). *P≤ 0.05, §P≤ 0.01, #P≤ 0.001. MBP myelin basic protein 1, HI hypoxia-ischemia,
SAL saline, MAPC multipotent adult progenitor cells, IR immunoreactivity. Scale bars: (a) 200 μm, (b) 100 μm
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MAPC prevented loss of baroreflex sensitivity after
global HI
Baroreceptor reflex sensitivity was analyzed to study the
effect of MAPC treatment on deeper brain functions sit-
uated in the brain stem (Fig. 7). Global HI increasingly
compromised baroreceptor reflex sensitivity over time
(sham-SAL vs. HI-SAL, significant for all time-points
with the exception of experimental day 1). MAPC sig-
nificantly prevented the loss of baroreflex sensitivity
(HI-SAL vs. HI-MAPC, significant on all time-points).
Discussion
Hypoxic-ischemic brain injury is common in preterm in-
fants. To date, no treatment options are available to re-
duce mortality and morbidity associated with brain
injury in preterm infants. Our group has previously
shown in a well-established pre-clinical model of global
hypoxic-ischemia (HI) that mesenchymal stem cells
(MSC) are a promising candidate for the treatment of
hypoxic-ischemic brain injury [2]. In the current study,
we investigated the neuroprotective capacity of multipo-
tent adult progenitor cells (MAPC), which are adherent
bone marrow-derived cells of an earlier developmental
stage than MSC and exhibiting more potent anti-
inflammatory and regenerative properties [3, 4, 6–10].
We showed that intravenous administration of MAPC
prevented functional and structural injury in the preterm
brain and modulated the cerebral and peripheral inflam-
matory response after global HI.
We administered MAPC cells 1 h and 4 days after glo-
bal HI. With the first dose, we aimed to dampen the acute
cerebral and peripheral inflammatory response, which
has been shown to evolve early after global hypoxia-
ischemia [2]. A pilot study in this model showed a sec-
ondary peak in seizure burden in untreated animals 4–5
days after global HI (unpublished data). Therefore, the
Fig. 5 MAPC prevented splenic involution and modulated the peripheral inflammatory response. a Splenic weight corrected for body weight (BW).
Global HI induced significant splenic involution, which was significantly prevented by MAPC; means ± 95 % CI and levels of significance are depicted,
which were calculated with ANOVA (sham-SAL n = 8, sham-MAPC n = 8, HI-SAL n = 8, HI-MAPC n = 8). b IL-10 mRNA levels were significantly increased
in the spleen 7 days after global HI. MAPC significantly attenuated the HI-induced IL-10 response in the spleen. c Splenic IFNγ mRNA levels
were significantly increased 7 days following global HI. MAPC treatment tended to reduce IFNγ mRNA levels. However, statistical significance
was not reached. d TNFα mRNA levels showed a trend to increase following global HI, which was significantly prevented by MAPC; geometric
means ± 95 % CI and levels of significance are depicted, which were calculated with ANOVA (sham-SAL n = 8, sham-MAPC n = 6, HI-SAL n = 8,
HI-MAPC n = 8). *P≤ 0.05, §P≤ 0.01, #P≤ 0.001. HI hypoxia-ischemia, SAL saline, MAPC multipotent adult progenitor cells, IFNγ interferon gamma, TNFα
tumor necrosis factor alpha
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second dose of MAPC cells was administered 4 days after
global HI aimed at preventing secondary functional
injury.
Our findings showed that MAPC cells 1 h and 4 days
after global HI reduced seizure burden after global HI
throughout the study period of 7 days. This finding is
clinically highly relevant, since several studies have
shown that seizures in term and preterm neonatal HIE
are associated with adverse neurodevelopmental outcome
[26–28]. In our model, we detected seizure activity with
amplitude-integrated EEG (aEEG), which is clinically used
to monitor neonatal brain function and has a high sensi-
tivity and specificity in predicting neurodevelopmental
outcomes in neonates with HI brain injury [29]. Recorded
seizure activity in our study was most likely located in the
cortical layers. However, since the electrodes were placed
directly on the dura, we may have recorded seizures
or electrophysiological responses originating from
Fig. 6 MAPC induced functional neuroprotection after global HI. Global HI caused a significant seizure burden indicated by an increased total
number (a) and duration of seizures (b) compared to controls. Administration of MAPC significantly reduced electrographic seizure number and
duration. Medians ± interquartile ranges (IQR) and levels of significance of the treatment effect (HI-SAL vs. HI-MAPC) are depicted, which were
calculated by Mann-Whitney test (HI-SAL n = 8, HI-MAPC n = 8). No electrographic seizure activity was detected under sham conditions. For clarity
purposes these sham groups (sham-SAL n = 8 and sham-MAPC n = 6) are not shown. *P ≤ 0.05, §P ≤ 0.01, #P≤ 0.001. HI hypoxia-ischemia, SAL
saline, MAPC multipotent adult progenitor cells
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deeper regions underlying the cortex (i.e., thalamus
and hippocampus). In addition to cortical grey matter
protection, the reduced seizure activity may therefore
also represent protection of deeper brain structures.
We therefore assessed the baroreceptor reflex as an
indicator for function of the brain stem. This is clin-
ically of importance since the baroreflex is a vital part
of the cardiovascular auto regulatory system in pre-
term infants, which secures adequate perfusion of the
preterm brain [22]. The cerebrovascular system is still
immature in prematurity, making the preterm brain
extremely vulnerable to fluctuations in blood pressure
caused by HI (or other adverse events such as infection)
[30]. Previously, we demonstrated that global HI disturbed
normal development of the baroreflex, which resulted in
impairment of heart rate-mediated blood pressure control
[22]. The fact that MAPC treatment at 1 h and 4 days im-
proved baroreflex sensitivity indicated that the therapeutic
effects reach as far as the highly conserved central brain
functions in the brainstem and supports the concept of
MAPC-induced protection against grey matter injury in
the hypoxic-ischemic preterm brain. The protection of
grey matter by MAPC after global HI may be explained by
findings of previous reports demonstrating that MAPC
improved neurogenesis and stimulated neurite outgrowth
and synaptogenesis [7, 31, 32].
Density of apoptotic cells in the subcortical white
matter was neither affected by global HI nor by MAPC
treatment in this study. The fact that we did not de-
tect significant changes in cell death is most likely ex-
plained by timing of assessment at 7 days after global
HI, while apoptotic cell death peaks earlier after cerebral
hypoxia-ischemia. Further studies on the dynamics of cell
death in after global HI are needed to determine the
therapeutic effect of MAPC on cellular loss in the preterm
brain.
MAPC have been previously shown to have potent
anti-inflammatory properties in pre-clinical studies of
traumatic and ischemic injury of the central nervous sys-
tem (CNS) [6–11]. Our study confirmed and extended
these findings in a translational model of hypoxic-
ischemic injury in the preterm brain by showing that
MAPC reduced the neuroinflammatory response in the
subcortical white matter (SCWM), as evidenced by re-
duced microglial proliferation. We and others have
shown that the microglial response is a reliable marker
for the cerebral inflammatory response that plays a piv-
otal role in the etiology of hypoxic-ischemic encephalop-
athy in the preterm brain [14, 33]. Although the size of
the treatment effect was modest, reduction of IBA-1 im-
munoreactivity was associated with functional and struc-
tural improvement, indicating that the modulation of
the microglial response was biologically relevant.
We postulate that the observed MAPC-induced reduc-
tion of cerebral inflammation after global HI may be ex-
plained by two mechanisms; firstly, MAPC have been
shown to induce a microglial-type switch from a pro-
inflammatory M1 phenotype to an anti-inflammatory
M2 phenotype, which is associated with reduced inflam-
mation in the CNS [8]. Secondly, MAPC may have re-
duced glutamate excitotoxicity in a similar fashion as
MSC, which were shown previously to inhibit glutamate
receptor expression and function, thereby inhibiting
microglial activation [34]. However, MAPC did not
Fig. 7 MAPC prevented loss of baroreflex sensitivity. Global HI caused a significant gradual decline of baroreflex sensitivity over time, which was
prevented by MAPC treatment; means ± 95 % CI and levels of significance of the treatment effect (HI-SAL vs. HI-MAPC) are depicted, which were
calculated by the Bayesian multi-level model. There were no differences in baroreflex sensitivity between the sham-SAL and sham-MAPC groups.
For clarity purposes, all sham-treated animals (sham-SAL n = 8 and sham-MAPC n = 6) were grouped and depicted as one sham group. HI-SAL
n = 8, HI-MAPC n = 8. *P ≤ 0.05, §P ≤ 0.01, #P ≤ 0.001. HI hypoxia-ischemia, SAL saline, MAPC multipotent adult progenitor cells
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attenuate the inflammatory response in the hippocampus.
These spatial differences in anti-inflammatory effects are
in line with previous data showing that the hippocampus
is more severely affected by hypoxia-ischemia, and there-
fore, injury may be irreversible [2, 14, 15].
White matter injury is the clinical hallmark of HI
brain injury in the preterm brain [35]. Consistent with
earlier studies [2, 14, 15], we demonstrated that global
hypoxia-ischemia induced marked hypomyelination of
the preterm brain, which was prevented by intravenous
administration of MAPC. Microglial-type switch and
subsequent reduction of cerebral inflammation has been
previously associated with remyelination [36, 37] and
may therefore explain the observed reduction of white
matter injury.
Besides attenuation of the cerebral inflammatory re-
sponse, our findings indicated that MAPC modulated
the peripheral inflammatory response, which has been
implicated in the etiology of hypoxic-ischemic injury in
the preterm brain [14, 38–40]. Our results showed that
MAPC prevented splenic involution. We have previously
shown in the current model that splenic involution after
global HI was caused by efflux of immune effector cells
[14]. Furthermore, our findings demonstrated that intra-
venous administration of MSC induced splenic T cell
tolerance [2]. The observed unresponsiveness of sple-
nic T cells was associated with reduced systemic
mobilization of immune effector cells and concomitant
reduction of brain-infiltrating immune cells resulting in
less severe inflammation in the preterm brain after glo-
bal HI [2]. Based on these findings, we postulate that
MAPC therapy reduced the mobilization of immune
effector cells from the spleen resulting in less extensive
invasion of these injurious cells into the brain. This con-
cept is supported by previous findings showing a spleen-
mediated neuroprotective effect of MAPC in traumatic
CNS injury [9, 11]. Recently, it was demonstrated that
splenic IFNγ plays a key role in injurious signaling to
the ischemic brain [41]. Functional elimination by splen-
ectomy or administration of IFNγ neutralizing anti-
bodies reduced brain injury after stroke [42]. In line with
these findings, reduction of cerebral inflammation (i.e.,
microglial proliferation) by MAPC treatment was associ-
ated with decreased splenic IFNγ levels. To determine
whether IFNγ from spleen cells is involved in preterm
brain injury after global HI, temporal dynamics of
splenic IFNγ release needs to be elucidated and its func-
tional role to be determined.
In our study, splenic IL-10 mRNA levels were not
altered by MAPC in sham conditions. Instead, we
found a marked increase of IL-10 mRNA under
hypoxic-ischemic conditions, which was attenuated by
administration of MAPC. We postulate that the ob-
served increase of splenic IL-10 mRNA after global HI is
part of an endogenous regenerative response after injury.
MAPC may have reduced the injurious load eliciting such
a response resulting in reduced IL-10 levels at the time of
assessment (7 days after global HI). This hypothesis is
supported by previous reports showing activation of
endogenous repair processes involving IL-10-mediated
T-reg mobilization after cerebral ischemia [39, 40, 43].
Furthermore, early administration of MSC was shown
to prevent progression of hypoxic-ischemic injury [2].
These findings suggest that early administration of
MAPC prevent injury before endogenous repair mech-
anisms, such as IL-10-mediated T-reg mobilization, are
activated.
In line with previous studies that report the clearance
of MAPC within 48–72 h [10, 31], we did not detect
MAPC in brain, spleen, or lung tissue 7 days after global
HI (i.e., 3 days after the second dose of MAPC). The fact
that we found MAPC-mediated therapeutic effects with-
out detectable presence of MAPC in the brain after
7 days of onset of hypoxia-ischemia, suggests that the
neuroprotective effects of MAPC last longer than their
presence. We postulate that this phenomenon can be ex-
plained by MAPC dampening the detrimental, periph-
eral, and cerebral inflammatory responses at an early
stage, before these responses can aggravate hypoxic-
ischemic injury in the preterm brain.
Our study has several limitations. We did not perform
a time series of histologic analysis to assess temporal
dynamics of global HI-induced injury, the cerebral and
peripheral inflammatory response, and therapeutic ef-
fects of intravenous MAPC administration. Moreover,
we did not discriminate between the therapeutic effect
between the first and second dose of MAPC cells. These
limitations are inherent to limited experimental groups
to make large animal experiments feasible. Unfortu-
nately, no ovine-specific antibodies are currently avail-
able to detect M1 and M2 microglial phenotypes in our
studies.
Our findings are clinically highly relevant for several
reasons. First, we tested our hypothesis in a well-
established pre-clinical animal in which global HI was
induced by transient umbilical cord occlusion accurately
mimicking the common etiology of hypoxic-ischemic
brain injury in preterm infants [44, 45]. Second, this
pre-clinical animal model allows for continuous in
utero registration of relevant parameters (i.e., vital pa-
rameters and aEEG) with strong clinical relevance
and predictive value, which gives more insight in HI-
induced pathophysiology and efficacy of therapeutic
options in a pre-clinical setting. Third, pre-clinical
studies have confirmed safety and genomic stability of
MAPC [5, 23], and MAPC therapy is currently being
tested in phase I/II clinical trials for the treatment of
ischemic stroke, graft-versus-host disease (GVHD),
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acute myocardial infarction, and inflammatory bowel
disease [4], emphasizing clinical applicability of these
cells.
Conclusions
In conclusion, we have shown in a pre-clinical animal
model that MAPC improve the functional and structural
outcome of the preterm brain after global HI. Future
studies should further establish the mechanism and
long-term therapeutic effects of MAPC-induced neuro-
protection in the developing preterm brain exposed to
hypoxia-ischemia. Our study may form the basis for
future clinical trials, which will evaluate whether
MAPC therapy is capable of reducing neurological se-
quelae in preterm infants with hypoxic-ischemic brain
injury.
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